购物车
全部删除
您的购物车当前为空
IBI-322 是靶向PD-L1和CD47的双特异性抗体。在单价结合状态下,IBI-322 能够减弱CD47的活性,而在双价结合时可以阻断PD-L1的活性。它选择性结合 CD47+PD-L1+ 肿瘤细胞,有效抑制 CD47-SIRPα 信号,并在体外引发强烈的肿瘤细胞吞噬作用。
IBI-322 是靶向PD-L1和CD47的双特异性抗体。在单价结合状态下,IBI-322 能够减弱CD47的活性,而在双价结合时可以阻断PD-L1的活性。它选择性结合 CD47+PD-L1+ 肿瘤细胞,有效抑制 CD47-SIRPα 信号,并在体外引发强烈的肿瘤细胞吞噬作用。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 12,000 | 待询 | |
| 5 mg | 待询 | 待询 |
IBI-322 相关产品
| 产品描述 | IBI-322 is a bispecific antibody targeting PD-L1 and CD47. In monovalent binding, it can attenuate the activity of CD47, and in bivalent binding, it can block the activity of PD-L1. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibiting the CD47-SIRPα signaling and inducing strong tumor cell phagocytosis in vitro. |
| 存储 | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
评论内容